Where Do We Stand with Targeted Therapy of Refractory Thyroid Cancer?—Utility of RECIST Criteria
Author:
Affiliation:
1. Section of Endocrinology and Metabolism, University of Siena, Italy.
Publisher
Mary Ann Liebert Inc
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Link
https://www.liebertpub.com/doi/pdf/10.1089/thy.2008.0038
Reference7 articles.
1. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
2. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma
3. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy
4. Thyroid Cancer Molecular Signaling Pathways and Use of Targeted Therapy
5. A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Knockdown of eIF3a attenuated cell growth in K1 human thyroid cancer cells;Genes & Genomics;2021-02-17
2. Tumor and normal thyroid spheroids: from tissues to zebrafish;Minerva Endocrinology;2018-01
3. Knockdown of S100A4 blocks growth and metastasis of anaplastic thyroid cancer cells in vitro and in vivo;Cancer Biomarkers;2016-09-26
4. New Therapies for Dedifferentiated Papillary Thyroid Cancer;International Journal of Molecular Sciences;2015-03-17
5. Treatment of differentiated thyroid cancer: New players on an old field;Drugs of the Future;2012
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3